BioPharma Resources

Drug Trial Radar · NCT07924111

A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 585 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

585

Planned (sponsor's estimate)

Start

Dec 30, 2026

Primary completion

Dec 30, 2029

Study completion Dec 30, 2030

Sponsor

Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, double-blind, multicenter phase iii clinical trial to evaluate the efficacy and safety of enlonstobart, with or without SYS6010 as adjuvant therapy, in participants with pathologically residual esophageal squamous cell carcinoma following complete surgical resection.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • SYS6010Drug

    SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker.

  • SG001Drug

    SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody.

  • SG001 placebo-mimickingDrug

    SG001 placebo-mimicking is a placebo mimicking of SG001

  • SYS6010 placebo-mimickingDrug

    SYS6010 placebo-mimicking is a placebo mimicking of SYS6010

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DFSTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.